Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascentage Pharma Group International ( (HK:6855) ) has provided an update.
Ascentage Pharma Group International has issued a supplemental notice confirming that its annual general meeting will proceed as scheduled in Suzhou on May 20, 2026, while adding two new ordinary resolutions. Shareholders will be asked to approve the grant of restricted share units and share options to Chairman and Executive Director Dr. Yang Dajun and executive Dr. Zhai under existing equity incentive schemes, signaling continued use of share-based rewards to retain key leadership.
The company is also replacing its original proxy form with a new one to reflect the additional resolutions, clarifying procedures for shareholders who have already or have not yet lodged proxies. These steps underscore the company’s emphasis on corporate governance compliance and transparent engagement with investors ahead of key compensation-related votes affecting senior management.
The most recent analyst rating on (HK:6855) stock is a Buy with a HK$93.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a Hong Kong-listed biopharmaceutical company incorporated in the Cayman Islands, with key operations in Suzhou, China. The company focuses on developing innovative oncology therapies and related pharmaceutical products for global markets, leveraging listings in both Hong Kong and U.S.-regulated environments to access international investors.
Average Trading Volume: 2,192,481
Technical Sentiment Signal: Hold
Current Market Cap: HK$16.58B
For a thorough assessment of 6855 stock, go to TipRanks’ Stock Analysis page.